APO Research
Talk to an analyst

APO RESEARCH · REPORT

Oral Solid Dosage Pharmaceutical Formulation

Compare research editions
View pricing & licenses

Selected research

Market Analysis & Forecast

Global Oral Solid Dosage Pharmaceutical Formulation Market Analysis and Forecast 2026-2032

22 December 2025195 pages

Choose your research edition.

Industry ResearchOral Solid Dosage Pharmaceutical Formulation Industry Research Report 2026115 pages · $2,950 USDIndustry Growth & TrendsGlobal Oral Solid Dosage Pharmaceutical Formulation Industry Growth and Trends Forecast to 203285 pages · $3,450 USDMarket StructureGlobal Oral Solid Dosage Pharmaceutical Formulation Market by Size, by Type, by Application, by Region, History and Forecast 2021-2032183 pages · $3,950 USDMarket Outlook & Growth OpportunitiesGlobal Oral Solid Dosage Pharmaceutical Formulation Market Outlook and Growth Opportunities 2026192 pages · $4,250 USDMarket Analysis & ForecastGlobal Oral Solid Dosage Pharmaceutical Formulation Market Analysis and Forecast 2026-2032195 pages · $4,950 USD

Market perspective

The global Oral Solid Dosage Pharmaceutical Formulation market is projected to grow from US$ million in 2026 to US$ million by 2032, at a Compound Annual Growth Rate (CAGR) of % during the forecast period.

The North America market for Oral Solid Dosage Pharmaceutical Formulation is estimated to increase from $ million in 2026 to reach $ million by 2032, at a CAGR of % during the forecast period of 2026 through 2032.

Europe market for Oral Solid Dosage Pharmaceutical Formulation is estimated to increase from $ million in 2026 to reach $ million by 2032, at a CAGR of % during the forecast period of 2026 through 2032.

Read the full market overview

Asia-Pacific market for Oral Solid Dosage Pharmaceutical Formulation is estimated to increase from $ million in 2026 to reach $ million by 2032, at a CAGR of % during the forecast period of 2026 through 2032.

The China market for Oral Solid Dosage Pharmaceutical Formulation is estimated to increase from $ million in 2026 to reach $ million by 2032, at a CAGR of % during the forecast period of 2026 through 2032.

The major global companies of Oral Solid Dosage Pharmaceutical Formulation include Novartis, Merck, Eli Lilly, Pfizer, AbbVie, AstraZeneca, Gilead, Bristol-Myers Squibb and Boehringer Ingelheim, etc. In 2025, the world's top three vendors accounted for approximately % of the revenue.

Report Includes

This report presents an overview of global market for Oral Solid Dosage Pharmaceutical Formulation, market size. Analyses of the global market trends, with historic market revenue data for 2021 - 2025, estimates for 2026, and projections of CAGR through 2032.

This report researches the key producers of Oral Solid Dosage Pharmaceutical Formulation, also provides the revenue of main regions and countries. Of the upcoming market potential for Oral Solid Dosage Pharmaceutical Formulation, and key regions or countries of focus to forecast this market into various segments and sub-segments. Country specific data and market value analysis for the U.S., Canada, Mexico, Brazil, China, Japan, South Korea, Southeast Asia, India, Germany, the U.K., Italy, Middle East, Africa, and Other Countries.

This report focuses on the Oral Solid Dosage Pharmaceutical Formulation revenue, market share and industry ranking of main manufacturers, data from 2021 to 2026. Identification of the major stakeholders in the global Oral Solid Dosage Pharmaceutical Formulation market, and analysis of their competitive landscape and market positioning based on recent developments and segmental revenues. This report will help stakeholders to understand the competitive landscape and gain more insights and position their businesses and market strategies in a better way.

This report analyzes the segments data by Type and by Application, revenue, and growth rate, from 2021 to 2032. Evaluation and forecast the market size for Oral Solid Dosage Pharmaceutical Formulation revenue, projected growth trends, production technology, application and end-user industry.

Oral Solid Dosage Pharmaceutical Formulation Segment by Company

Novartis

Merck

Eli Lilly

Pfizer

AbbVie

AstraZeneca

Gilead

Bristol-Myers Squibb

Boehringer Ingelheim

Oral Solid Dosage Pharmaceutical Formulation Segment by Type

Immediate Release

Extended Release

Others

Oral Solid Dosage Pharmaceutical Formulation Segment by Application

Hospital Pharmacy

Drug Stores

Retail Pharmacy

Others

Oral Solid Dosage Pharmaceutical Formulation Segment by Region

North America

United States

Canada

Mexico

Europe

Germany

France

U.K.

Italy

Russia

Spain

Netherlands

Switzerland

Sweden

Poland

Asia-Pacific

China

Japan

South Korea

India

Australia

Taiwan

Southeast Asia

South America

Brazil

Argentina

Chile

Middle East & Africa

Egypt

South Africa

Israel

Türkiye

GCC Countries

Study Objectives

1. To analyze and research the global status and future forecast, involving growth rate (CAGR), market share, historical and forecast.

2. To present the key players, revenue, market share, and Recent Developments.

3. To split the breakdown data by regions, type, manufacturers, and Application.

4. To analyze the global and key regions market potential and advantage, opportunity and challenge, restraints, and risks.

5. To identify significant trends, drivers, influence factors in global and regions.

6. To analyze competitive developments such as expansions, agreements, new product launches, and acquisitions in the market.

Reasons to Buy This Report

1. This report will help the readers to understand the competition within the industries and strategies for the competitive environment to enhance the potential profit. The report also focuses on the competitive landscape of the global Oral Solid Dosage Pharmaceutical Formulation market, and introduces in detail the market share, industry ranking, competitor ecosystem, market performance, new product development, operation situation, expansion, and acquisition. etc. of the main players, which helps the readers to identify the main competitors and deeply understand the competition pattern of the market.

2. This report will help stakeholders to understand the global industry status and trends of Oral Solid Dosage Pharmaceutical Formulation and provides them with information on key market drivers, restraints, challenges, and opportunities.

3. This report will help stakeholders to understand competitors better and gain more insights to strengthen their position in their businesses. The competitive landscape section includes the market share and rank (in market size), competitor ecosystem, new product development, expansion, and acquisition.

4. This report stays updated with novel technology integration, features, and the latest developments in the market.

5. This report helps stakeholders to gain insights into which regions to target globally.

6. This report helps stakeholders to gain insights into the end-user perception concerning the adoption of Oral Solid Dosage Pharmaceutical Formulation.

7. This report helps stakeholders to identify some of the key players in the market and understand their valuable contribution.

Chapter Outline

Chapter 1: Introduces the report scope of the report, executive summary of different market segments (product type, application, etc), including the market size of each market segment, future development potential, and so on. It offers a high-level view of the current state of the market and its likely evolution in the short to mid-term, and long term.

Chapter 2: Introduces the market dynamics, latest developments of the market, the driving factors and restrictive factors of the market, the challenges and risks faced by manufacturers in the industry, and the analysis of relevant policies in the industry.

Chapter 3: Revenue of Oral Solid Dosage Pharmaceutical Formulation in global and regional level. It provides a quantitative analysis of the market size and development potential of each region and its main countries and introduces the market development, future development prospects, market space, and capacity of each country in the world.

Chapter 4: Detailed analysis of Oral Solid Dosage Pharmaceutical Formulation company competitive landscape, revenue, market share and industry ranking, latest development plan, merger, and acquisition information, etc.

Chapter 5: Provides the analysis of various market segments by type, covering the revenue, and development potential of each market segment, to help readers find the blue ocean market in different market segments.

Chapter 6: Provides the analysis of various market segments by application, covering the revenue, and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.

Chapter 7: Provides profiles of key companies, introducing the basic situation of the main companies in the market in detail, including product descriptions and specifications, Oral Solid Dosage Pharmaceutical Formulation revenue, gross margin, and recent development, etc.

Chapter 8: North America by type, by application and by country, revenue for each segment.

Chapter 9: Europe by type, by application and by country, revenue for each segment.

Chapter 10: China type, by application, revenue for each segment.

Chapter 11: Asia (excluding China) type, by application and by region, revenue for each segment.

Chapter 12: South America, Middle East and Africa by type, by application and by country, revenue for each segment.

Chapter 13: The main concluding insights of the report.

More report detail

Tables and figures
List of Tables Table 1. Global Oral Solid Dosage Pharmaceutical Formulation Market Size Growth Rate by Type (US$ Million), 2021 VS 2025 VS 2032 Table 2. Immediate Release Major Player Table 3. Extended Release Major Player Table 4. Others Major Player Table 5. Global Oral Solid Dosage Pharmaceutical Formulation Market Size Growth Rate by Application (US$ Million), 2021 VS 2025 VS 2032 Table 6. Hospital Pharmacy Major Player Table 7. Drug Stores Major Player Table 8. Retail Pharmacy Major Player Table 9. Others Major Player Table 10. Oral Solid Dosage Pharmaceutical Formulation Industry Trends Table 11. Oral Solid Dosage Pharmaceutical Formulation Industry Drivers Table 12. Oral Solid Dosage Pharmaceutical Formulation Industry Opportunities and Challenges Table 13. Oral Solid Dosage Pharmaceutical Formulation Industry Restraints Table 14. Global Oral Solid Dosage Pharmaceutical Formulation Market Size Growth Rate (CAGR) by Region (US$ Million): 2021 VS 2025 VS 2032 Table 15. Global Oral Solid Dosage Pharmaceutical Formulation Market Size by Region (2021-2026) & (US$ Million) Table 16. Global Oral Solid Dosage Pharmaceutical Formulation Market Share by Region (2021-2026) Table 17. Global Oral Solid Dosage Pharmaceutical Formulation Market Size by Region (2027-2032) & (US$ Million) Table 18. Global Oral Solid Dosage Pharmaceutical Formulation Market Share by Region (2027-2032) Table 19. Global Oral Solid Dosage Pharmaceutical Formulation Revenue by Players (US$ Million) & (2021-2026) Table 20. Global Oral Solid Dosage Pharmaceutical Formulation Revenue Market Share by Players (2021-2026) Table 21. Global Oral Solid Dosage Pharmaceutical Formulation Key Players Ranking, 2024 VS 2025 VS 2026 Table 22. Global Oral Solid Dosage Pharmaceutical Formulation Key Players Headquarters & Area Served Table 23. Global Oral Solid Dosage Pharmaceutical Formulation Players, Product Type & Application Table 24. Global Oral Solid Dosage Pharmaceutical Formulation Players Establishment Date Table 25. Global Players Market Concentration Ratio (CR5 and HHI) Table 26. Global Oral Solid Dosage Pharmaceutical Formulation by Players Type (Tier 1, Tier 2, and Tier 3) & (Based on the Revenue of 2025) Table 27. Global Oral Solid Dosage Pharmaceutical Formulation Revenue by Type 2021 VS 2025 VS 2032 (US$ Million) Table 28. Global Oral Solid Dosage Pharmaceutical Formulation Revenue by Type (2021-2026) & (US$ Million) Table 29. Global Oral Solid Dosage Pharmaceutical Formulation Revenue by Type (2027-2032) & (US$ Million) Table 30. Global Oral Solid Dosage Pharmaceutical Formulation Revenue Market Share by Type (2021-2026) Table 31. Global Oral Solid Dosage Pharmaceutical Formulation Revenue Market Share by Type (2027-2032) Table 32. Global Oral Solid Dosage Pharmaceutical Formulation Revenue by Application 2021 VS 2025 VS 2032 (US$ Million) Table 33. Global Oral Solid Dosage Pharmaceutical Formulation Revenue by Application (2021-2026) & (US$ Million) Table 34. Global Oral Solid Dosage Pharmaceutical Formulation Revenue by Application (2027-2032) & (US$ Million) Table 35. Global Oral Solid Dosage Pharmaceutical Formulation Revenue Market Share by Application (2021-2026) Table 36. Global Oral Solid Dosage Pharmaceutical Formulation Revenue Market Share by Application (2027-2032) Table 37. Novartis Company Information Table 38. Novartis Business Overview Table 39. Novartis Oral Solid Dosage Pharmaceutical Formulation Revenue and Gross Margin (US$ Million) & (2021-2026) Table 40. Novartis Oral Solid Dosage Pharmaceutical Formulation Product Portfolio Table 41. Novartis Recent Development Table 42. Merck Company Information Table 43. Merck Business Overview Table 44. Merck Oral Solid Dosage Pharmaceutical Formulation Revenue and Gross Margin (US$ Million) & (2021-2026) Table 45. Merck Oral Solid Dosage Pharmaceutical Formulation Product Portfolio Table 46. Merck Recent Development Table 47. Eli Lilly Company Information Table 48. Eli Lilly Business Overview Table 49. Eli Lilly Oral Solid Dosage Pharmaceutical Formulation Revenue and Gross Margin (US$ Million) & (2021-2026) Table 50. Eli Lilly Oral Solid Dosage Pharmaceutical Formulation Product Portfolio Table 51. Eli Lilly Recent Development Table 52. Pfizer Company Information Table 53. Pfizer Business Overview Table 54. Pfizer Oral Solid Dosage Pharmaceutical Formulation Revenue and Gross Margin (US$ Million) & (2021-2026) Table 55. Pfizer Oral Solid Dosage Pharmaceutical Formulation Product Portfolio Table 56. Pfizer Recent Development Table 57. AbbVie Company Information Table 58. AbbVie Business Overview Table 59. AbbVie Oral Solid Dosage Pharmaceutical Formulation Revenue and Gross Margin (US$ Million) & (2021-2026) Table 60. AbbVie Oral Solid Dosage Pharmaceutical Formulation Product Portfolio Table 61. AbbVie Recent Development Table 62. AstraZeneca Company Information Table 63. AstraZeneca Business Overview Table 64. AstraZeneca Oral Solid Dosage Pharmaceutical Formulation Revenue and Gross Margin (US$ Million) & (2021-2026) Table 65. AstraZeneca Oral Solid Dosage Pharmaceutical Formulation Product Portfolio Table 66. AstraZeneca Recent Development Table 67. Gilead Company Information Table 68. Gilead Business Overview Table 69. Gilead Oral Solid Dosage Pharmaceutical Formulation Revenue and Gross Margin (US$ Million) & (2021-2026) Table 70. Gilead Oral Solid Dosage Pharmaceutical Formulation Product Portfolio Table 71. Gilead Recent Development Table 72. Bristol-Myers Squibb Company Information Table 73. Bristol-Myers Squibb Business Overview Table 74. Bristol-Myers Squibb Oral Solid Dosage Pharmaceutical Formulation Revenue and Gross Margin (US$ Million) & (2021-2026) Table 75. Bristol-Myers Squibb Oral Solid Dosage Pharmaceutical Formulation Product Portfolio Table 76. Bristol-Myers Squibb Recent Development Table 77. Boehringer Ingelheim Company Information Table 78. Boehringer Ingelheim Business Overview Table 79. Boehringer Ingelheim Oral Solid Dosage Pharmaceutical Formulation Revenue and Gross Margin (US$ Million) & (2021-2026) Table 80. Boehringer Ingelheim Oral Solid Dosage Pharmaceutical Formulation Product Portfolio Table 81. Boehringer Ingelheim Recent Development Table 82. North America Oral Solid Dosage Pharmaceutical Formulation Revenue by Type (2021-2026) & (US$ Million) Table 83. North America Oral Solid Dosage Pharmaceutical Formulation Revenue by Type (2027-2032) & (US$ Million) Table 84. North America Oral Solid Dosage Pharmaceutical Formulation Revenue by Application (2021-2026) & (US$ Million) Table 85. North America Oral Solid Dosage Pharmaceutical Formulation Revenue by Application (2027-2032) & (US$ Million) Table 86. North America Oral Solid Dosage Pharmaceutical Formulation Revenue by Country (2021 VS 2025 VS 2032) & (US$ Million) Table 87. North America Oral Solid Dosage Pharmaceutical Formulation Revenue by Country (2021-2026) & (US$ Million) Table 88. North America Oral Solid Dosage Pharmaceutical Formulation Revenue by Country (US$ Million) & (2027-2032) Table 89. Europe Oral Solid Dosage Pharmaceutical Formulation Revenue by Type (2021-2026) & (US$ Million) Table 90. Europe Oral Solid Dosage Pharmaceutical Formulation Revenue by Type (2027-2032) & (US$ Million) Table 91. Europe Oral Solid Dosage Pharmaceutical Formulation Revenue by Application (2021-2026) & (US$ Million) Table 92. Europe Oral Solid Dosage Pharmaceutical Formulation Revenue by Application (2027-2032) & (US$ Million) Table 93. Europe Oral Solid Dosage Pharmaceutical Formulation Revenue by Country (2021 VS 2025 VS 2032) & (US$ Million) Table 94. Europe Oral Solid Dosage Pharmaceutical Formulation Revenue by Country (2021-2026) & (US$ Million) Table 95. Europe Oral Solid Dosage Pharmaceutical Formulation Revenue by Country (US$ Million) & (2027-2032) Table 96. China Oral Solid Dosage Pharmaceutical Formulation Revenue by Type (2021-2026) & (US$ Million) Table 97. China Oral Solid Dosage Pharmaceutical Formulation Revenue by Type (2027-2032) & (US$ Million) Table 98. China Oral Solid Dosage Pharmaceutical Formulation Revenue by Application (2021-2026) & (US$ Million) Table 99. China Oral Solid Dosage Pharmaceutical Formulation Revenue by Application (2027-2032) & (US$ Million) Table 100. Asia Oral Solid Dosage Pharmaceutical Formulation Revenue by Type (2021-2026) & (US$ Million) Table 101. Asia Oral Solid Dosage Pharmaceutical Formulation Revenue by Type (2027-2032) & (US$ Million) Table 102. Asia Oral Solid Dosage Pharmaceutical Formulation Revenue by Application (2021-2026) & (US$ Million) Table 103. Asia Oral Solid Dosage Pharmaceutical Formulation Revenue by Application (2027-2032) & (US$ Million) Table 104. Asia Oral Solid Dosage Pharmaceutical Formulation Revenue by Region (2021 VS 2025 VS 2032) & (US$ Million) Table 105. Asia Oral Solid Dosage Pharmaceutical Formulation Revenue by Region (US$ Million) & (2021-2026) Table 106. Asia Oral Solid Dosage Pharmaceutical Formulation Revenue by Region (US$ Million) & (2027-2032) Table 107. SAMEA Oral Solid Dosage Pharmaceutical Formulation Revenue by Type (2021-2026) & (US$ Million) Table 108. SAMEA Oral Solid Dosage Pharmaceutical Formulation Revenue by Type (2027-2032) & (US$ Million) Table 109. SAMEA Oral Solid Dosage Pharmaceutical Formulation Revenue by Application (2021-2026) & (US$ Million) Table 110. SAMEA Oral Solid Dosage Pharmaceutical Formulation Revenue by Application (2027-2032) & (US$ Million) Table 111. SAMEA Oral Solid Dosage Pharmaceutical Formulation Revenue by Country (2021 VS 2025 VS 2032) & (US$ Million) Table 112. SAMEA Oral Solid Dosage Pharmaceutical Formulation Revenue by Country (2021-2026) & (US$ Million) Table 113. SAMEA Oral Solid Dosage Pharmaceutical Formulation Revenue by Country (US$ Million) & (2027-2032) Table 114. Research Programs/Design for This Report Table 115. Authors List of This Report Table 116. Secondary Sources Table 117. Primary Sources List of Figures Figure 1. Oral Solid Dosage Pharmaceutical Formulation Image Figure 2. Global Oral Solid Dosage Pharmaceutical Formulation Market Size Growth Rate by Type (US$ Million), 2021 VS 2025 VS 2032 Figure 3. Global Oral Solid Dosage Pharmaceutical Formulation Market Size Share 2021 VS 2025 VS 2032 Figure 4. Immediate Release Image Figure 5. Extended Release Image Figure 6. Others Image Figure 7. Global Oral Solid Dosage Pharmaceutical Formulation Market Size Growth Rate by Application (US$ Million), 2021 VS 2025 VS 2032 Figure 8. Global Oral Solid Dosage Pharmaceutical Formulation Market Size Share 2021 VS 2025 VS 2032 Figure 9. Hospital Pharmacy Image Figure 10. Drug Stores Image Figure 11. Retail Pharmacy Image Figure 12. Others Image Figure 13. Global Oral Solid Dosage Pharmaceutical Formulation Market Size (US$ Million) & (2021-2032) Figure 14. Global Oral Solid Dosage Pharmaceutical Formulation Market Size, (US$ Million), 2021 VS 2025 VS 2032 Figure 15. Global Oral Solid Dosage Pharmaceutical Formulation Market Share by Region: 2021 VS 2025 VS 2032 Figure 16. Global Oral Solid Dosage Pharmaceutical Formulation Players Revenue Share Top 10 and Top 5 in 2025 Figure 17. Players Type (Tier 1, Tier 2, and Tier 3): 2021 VS 2025 Figure 18. Global Oral Solid Dosage Pharmaceutical Formulation Revenue by Type (2021 VS 2025 VS 2032) & (US$ Million) Figure 19. Global Oral Solid Dosage Pharmaceutical Formulation Revenue Market Share 2021 VS 2025 VS 2032 Figure 20. Global Oral Solid Dosage Pharmaceutical Formulation Revenue Market Share by Type (2021-2032) Figure 21. Global Oral Solid Dosage Pharmaceutical Formulation Revenue by Application (2021 VS 2025 VS 2032) & (US$ Million) Figure 22. Global Oral Solid Dosage Pharmaceutical Formulation Revenue Market Share by Application (2021 VS 2025 VS 2032) Figure 23. Global Oral Solid Dosage Pharmaceutical Formulation Revenue Market Share by Application (2021-2032) Figure 24. North America Oral Solid Dosage Pharmaceutical Formulation Revenue YoY Growth (2021-2032) & (US$ Million) Figure 25. North America Oral Solid Dosage Pharmaceutical Formulation Revenue Share by Type (2021-2032) Figure 26. North America Oral Solid Dosage Pharmaceutical Formulation Revenue Share by Application (2021-2032) Figure 27. North America Oral Solid Dosage Pharmaceutical Formulation Revenue Share by Country (2021-2032) Figure 28. United States Oral Solid Dosage Pharmaceutical Formulation Revenue YoY Growth (US$ Million) & (2021-2032) Figure 29. Canada Oral Solid Dosage Pharmaceutical Formulation Revenue YoY Growth (US$ Million) & (2021-2032) Figure 30. Mexico Oral Solid Dosage Pharmaceutical Formulation Revenue YoY Growth (US$ Million) & (2021-2032) Figure 31. Europe Oral Solid Dosage Pharmaceutical Formulation Revenue YoY Growth (2021-2032) & (US$ Million) Figure 32. Europe Oral Solid Dosage Pharmaceutical Formulation Revenue Share by Type (2021-2032) Figure 33. Europe Oral Solid Dosage Pharmaceutical Formulation Revenue Share by Application (2021-2032) Figure 34. Europe Oral Solid Dosage Pharmaceutical Formulation Revenue Share by Country (2021-2032) Figure 35. Germany Oral Solid Dosage Pharmaceutical Formulation Revenue YoY Growth (US$ Million) & (2021-2032) Figure 36. France Oral Solid Dosage Pharmaceutical Formulation Revenue YoY Growth (US$ Million) & (2021-2032) Figure 37. U.K. Oral Solid Dosage Pharmaceutical Formulation Revenue YoY Growth (US$ Million) & (2021-2032) Figure 38. Italy Oral Solid Dosage Pharmaceutical Formulation Revenue YoY Growth (US$ Million) & (2021-2032) Figure 39. Spain Oral Solid Dosage Pharmaceutical Formulation Revenue YoY Growth (US$ Million) & (2021-2032) Figure 40. Russia Oral Solid Dosage Pharmaceutical Formulation Revenue YoY Growth (US$ Million) & (2021-2032) Figure 41. Netherlands Oral Solid Dosage Pharmaceutical Formulation Revenue YoY Growth (US$ Million) & (2021-2032) Figure 42. Nordic Countries Oral Solid Dosage Pharmaceutical Formulation Revenue YoY Growth (US$ Million) & (2021-2032) Figure 43. China Oral Solid Dosage Pharmaceutical Formulation Revenue YoY Growth (2021-2032) & (US$ Million) Figure 44. China Oral Solid Dosage Pharmaceutical Formulation Revenue Share by Type (2021-2032) Figure 45. China Oral Solid Dosage Pharmaceutical Formulation Revenue Share by Application (2021-2032) Figure 46. Asia Oral Solid Dosage Pharmaceutical Formulation Revenue YoY Growth (2021-2032) & (US$ Million) Figure 47. Asia Oral Solid Dosage Pharmaceutical Formulation Revenue Share by Type (2021-2032) Figure 48. Asia Oral Solid Dosage Pharmaceutical Formulation Revenue Share by Application (2021-2032) Figure 49. Asia Oral Solid Dosage Pharmaceutical Formulation Revenue Share by Region (2021-2032) Figure 50. Japan Oral Solid Dosage Pharmaceutical Formulation Revenue YoY Growth (US$ Million) & (2021-2032) Figure 51. South Korea Oral Solid Dosage Pharmaceutical Formulation Revenue YoY Growth (US$ Million) & (2021-2032) Figure 52. India Oral Solid Dosage Pharmaceutical Formulation Revenue YoY Growth (US$ Million) & (2021-2032) Figure 53. Australia Oral Solid Dosage Pharmaceutical Formulation Revenue YoY Growth (US$ Million) & (2021-2032) Figure 54. Taiwan Oral Solid Dosage Pharmaceutical Formulation Revenue YoY Growth (US$ Million) & (2021-2032) Figure 55. Southeast Asia Oral Solid Dosage Pharmaceutical Formulation Revenue YoY Growth (US$ Million) & (2021-2032) Figure 56. SAMEA Oral Solid Dosage Pharmaceutical Formulation Revenue YoY Growth (2021-2032) & (US$ Million) Figure 57. SAMEA Oral Solid Dosage Pharmaceutical Formulation Revenue Share by Type (2021-2032) Figure 58. SAMEA Oral Solid Dosage Pharmaceutical Formulation Revenue Share by Application (2021-2032) Figure 59. SAMEA Oral Solid Dosage Pharmaceutical Formulation Revenue Share by Country (2021-2032) Figure 60. Brazil Oral Solid Dosage Pharmaceutical Formulation Revenue YoY Growth (US$ Million) & (2021-2032) Figure 61. Argentina Oral Solid Dosage Pharmaceutical Formulation Revenue YoY Growth (US$ Million) & (2021-2032) Figure 62. Chile Oral Solid Dosage Pharmaceutical Formulation Revenue YoY Growth (US$ Million) & (2021-2032) Figure 63. Colombia Oral Solid Dosage Pharmaceutical Formulation Revenue YoY Growth (US$ Million) & (2021-2032) Figure 64. Peru Oral Solid Dosage Pharmaceutical Formulation Revenue YoY Growth (US$ Million) & (2021-2032) Figure 65. Saudi Arabia Oral Solid Dosage Pharmaceutical Formulation Revenue YoY Growth (US$ Million) & (2021-2032) Figure 66. Israel Oral Solid Dosage Pharmaceutical Formulation Revenue YoY Growth (US$ Million) & (2021-2032) Figure 67. UAE Oral Solid Dosage Pharmaceutical Formulation Revenue YoY Growth (US$ Million) & (2021-2032) Figure 68. Turkey Oral Solid Dosage Pharmaceutical Formulation Revenue YoY Growth (US$ Million) & (2021-2032) Figure 69. Iran Oral Solid Dosage Pharmaceutical Formulation Revenue YoY Growth (US$ Million) & (2021-2032) Figure 70. Egypt Oral Solid Dosage Pharmaceutical Formulation Revenue YoY Growth (US$ Million) & (2021-2032) Figure 71. Years Considered Figure 72. Research Process Figure 73. Key Executives Interviewed

Scope & coverage.

Types
  • Immediate Release
  • Extended Release
  • Others
Applications
  • Hospital Pharmacy
  • Drug Stores
  • Retail Pharmacy
  • Others
Companies covered
  • Novartis
  • Merck
  • Eli Lilly
  • Pfizer
  • AbbVie
  • AstraZeneca
  • Gilead
  • Bristol-Myers Squibb
  • Boehringer Ingelheim

Inside the report.

1 Market Overview
  1. 1.1 Product Definition
  2. 1.2 Oral Solid Dosage Pharmaceutical Formulation Market by Type
  3. 1.2.1 Global Oral Solid Dosage Pharmaceutical Formulation Market Size by Type, 2021 VS 2025 VS 2032
  4. 1.2.2 Immediate Release
  5. 1.2.3 Extended Release
  6. 1.2.4 Others
  7. 1.3 Oral Solid Dosage Pharmaceutical Formulation Market by Application
  8. 1.3.1 Global Oral Solid Dosage Pharmaceutical Formulation Market Size by Application, 2021 VS 2025 VS 2032
  9. 1.3.2 Hospital Pharmacy
  10. 1.3.3 Drug Stores
  11. 1.3.4 Retail Pharmacy
  12. 1.3.5 Others
  13. 1.4 Assumptions and Limitations
  14. 1.5 Study Goals and Objectives
2 Oral Solid Dosage Pharmaceutical Formulation Market Dynamics
  1. 2.1 Oral Solid Dosage Pharmaceutical Formulation Industry Trends
  2. 2.2 Oral Solid Dosage Pharmaceutical Formulation Industry Drivers
  3. 2.3 Oral Solid Dosage Pharmaceutical Formulation Industry Opportunities and Challenges
  4. 2.4 Oral Solid Dosage Pharmaceutical Formulation Industry Restraints
3 Global Growth Perspective
  1. 3.1 Global Oral Solid Dosage Pharmaceutical Formulation Market Perspective (2021-2032)
  2. 3.2 Global Oral Solid Dosage Pharmaceutical Formulation Growth Trends by Region
  3. 3.2.1 Global Oral Solid Dosage Pharmaceutical Formulation Market Size by Region: 2021 VS 2025 VS 2032
  4. 3.2.2 Global Oral Solid Dosage Pharmaceutical Formulation Market Size by Region (2021-2026)
  5. 3.2.3 Global Oral Solid Dosage Pharmaceutical Formulation Market Size by Region (2027-2032)
4 Competitive Landscape by Players
  1. 4.1 Global Oral Solid Dosage Pharmaceutical Formulation Revenue by Players
  2. 4.1.1 Global Oral Solid Dosage Pharmaceutical Formulation Revenue by Players (2021-2026)
  3. 4.1.2 Global Oral Solid Dosage Pharmaceutical Formulation Revenue Market Share by Players (2021-2026)
  4. 4.1.3 Global Oral Solid Dosage Pharmaceutical Formulation Players Revenue Share Top 10 and Top 5 in 2025
  5. 4.2 Global Oral Solid Dosage Pharmaceutical Formulation Key Players Ranking, 2024 VS 2025 VS 2026
  6. 4.3 Global Oral Solid Dosage Pharmaceutical Formulation Key Players Headquarters & Area Served
  7. 4.4 Global Oral Solid Dosage Pharmaceutical Formulation Players, Product Type & Application
  8. 4.5 Global Oral Solid Dosage Pharmaceutical Formulation Players Establishment Date
  9. 4.6 Market Competitive Analysis
  10. 4.6.1 Global Oral Solid Dosage Pharmaceutical Formulation Market CR5 and HHI
  11. 4.6.3 2025 Oral Solid Dosage Pharmaceutical Formulation Tier 1, Tier 2, and Tier 3
5 Oral Solid Dosage Pharmaceutical Formulation Market Size by Type
  1. 5.1 Global Oral Solid Dosage Pharmaceutical Formulation Revenue by Type (2021 VS 2025 VS 2032)
  2. 5.2 Global Oral Solid Dosage Pharmaceutical Formulation Revenue by Type (2021-2032)
  3. 5.3 Global Oral Solid Dosage Pharmaceutical Formulation Revenue Market Share by Type (2021-2032)
6 Oral Solid Dosage Pharmaceutical Formulation Market Size by Application
  1. 6.1 Global Oral Solid Dosage Pharmaceutical Formulation Revenue by Application (2021 VS 2025 VS 2032)
  2. 6.2 Global Oral Solid Dosage Pharmaceutical Formulation Revenue by Application (2021-2032)
  3. 6.3 Global Oral Solid Dosage Pharmaceutical Formulation Revenue Market Share by Application (2021-2032)
7 Company Profiles
  1. 7.1 Novartis
  2. 7.1.1 Novartis Company Information
  3. 7.1.2 Novartis Business Overview
  4. 7.1.3 Novartis Oral Solid Dosage Pharmaceutical Formulation Revenue and Gross Margin (2021-2026)
  5. 7.1.4 Novartis Oral Solid Dosage Pharmaceutical Formulation Product Portfolio
  6. 7.1.5 Novartis Recent Developments
  7. 7.2 Merck
  8. 7.2.1 Merck Company Information
  9. 7.2.2 Merck Business Overview
  10. 7.2.3 Merck Oral Solid Dosage Pharmaceutical Formulation Revenue and Gross Margin (2021-2026)
  11. 7.2.4 Merck Oral Solid Dosage Pharmaceutical Formulation Product Portfolio
  12. 7.2.5 Merck Recent Developments
  13. 7.3 Eli Lilly
  14. 7.3.1 Eli Lilly Company Information
  15. 7.3.2 Eli Lilly Business Overview
  16. 7.3.3 Eli Lilly Oral Solid Dosage Pharmaceutical Formulation Revenue and Gross Margin (2021-2026)
  17. 7.3.4 Eli Lilly Oral Solid Dosage Pharmaceutical Formulation Product Portfolio
  18. 7.3.5 Eli Lilly Recent Developments
  19. 7.4 Pfizer
  20. 7.4.1 Pfizer Company Information
  21. 7.4.2 Pfizer Business Overview
  22. 7.4.3 Pfizer Oral Solid Dosage Pharmaceutical Formulation Revenue and Gross Margin (2021-2026)
  23. 7.4.4 Pfizer Oral Solid Dosage Pharmaceutical Formulation Product Portfolio
  24. 7.4.5 Pfizer Recent Developments
  25. 7.5 AbbVie
  26. 7.5.1 AbbVie Company Information
  27. 7.5.2 AbbVie Business Overview
  28. 7.5.3 AbbVie Oral Solid Dosage Pharmaceutical Formulation Revenue and Gross Margin (2021-2026)
  29. 7.5.4 AbbVie Oral Solid Dosage Pharmaceutical Formulation Product Portfolio
  30. 7.5.5 AbbVie Recent Developments
  31. 7.6 AstraZeneca
  32. 7.6.1 AstraZeneca Company Information
  33. 7.6.2 AstraZeneca Business Overview
  34. 7.6.3 AstraZeneca Oral Solid Dosage Pharmaceutical Formulation Revenue and Gross Margin (2021-2026)
  35. 7.6.4 AstraZeneca Oral Solid Dosage Pharmaceutical Formulation Product Portfolio
  36. 7.6.5 AstraZeneca Recent Developments
  37. 7.7 Gilead
  38. 7.7.1 Gilead Company Information
  39. 7.7.2 Gilead Business Overview
  40. 7.7.3 Gilead Oral Solid Dosage Pharmaceutical Formulation Revenue and Gross Margin (2021-2026)
  41. 7.7.4 Gilead Oral Solid Dosage Pharmaceutical Formulation Product Portfolio
  42. 7.7.5 Gilead Recent Developments
  43. 7.8 Bristol-Myers Squibb
  44. 7.8.1 Bristol-Myers Squibb Company Information
  45. 7.8.2 Bristol-Myers Squibb Business Overview
  46. 7.8.3 Bristol-Myers Squibb Oral Solid Dosage Pharmaceutical Formulation Revenue and Gross Margin (2021-2026)
  47. 7.8.4 Bristol-Myers Squibb Oral Solid Dosage Pharmaceutical Formulation Product Portfolio
  48. 7.8.5 Bristol-Myers Squibb Recent Developments
  49. 7.9 Boehringer Ingelheim
  50. 7.9.1 Boehringer Ingelheim Company Information
  51. 7.9.2 Boehringer Ingelheim Business Overview
  52. 7.9.3 Boehringer Ingelheim Oral Solid Dosage Pharmaceutical Formulation Revenue and Gross Margin (2021-2026)
  53. 7.9.4 Boehringer Ingelheim Oral Solid Dosage Pharmaceutical Formulation Product Portfolio
  54. 7.9.5 Boehringer Ingelheim Recent Developments
8 North America
  1. 8.1 North America Oral Solid Dosage Pharmaceutical Formulation Revenue (2021-2032)
  2. 8.2 North America Oral Solid Dosage Pharmaceutical Formulation Revenue by Type (2021-2032)
  3. 8.2.1 North America Oral Solid Dosage Pharmaceutical Formulation Revenue by Type (2021-2026)
  4. 8.2.2 North America Oral Solid Dosage Pharmaceutical Formulation Revenue by Type (2027-2032)
  5. 8.3 North America Oral Solid Dosage Pharmaceutical Formulation Revenue Share by Type (2021-2032)
  6. 8.4 North America Oral Solid Dosage Pharmaceutical Formulation Revenue by Application (2021-2032)
  7. 8.4.1 North America Oral Solid Dosage Pharmaceutical Formulation Revenue by Application (2021-2026)
  8. 8.4.2 North America Oral Solid Dosage Pharmaceutical Formulation Revenue by Application (2027-2032)
  9. 8.5 North America Oral Solid Dosage Pharmaceutical Formulation Revenue Share by Application (2021-2032)
  10. 8.6 North America Oral Solid Dosage Pharmaceutical Formulation Revenue by Country
  11. 8.6.1 North America Oral Solid Dosage Pharmaceutical Formulation Revenue by Country (2021 VS 2025 VS 2032)
  12. 8.6.2 North America Oral Solid Dosage Pharmaceutical Formulation Revenue by Country (2021-2026)
  13. 8.6.3 North America Oral Solid Dosage Pharmaceutical Formulation Revenue by Country (2027-2032)
  14. 8.6.4 United States
  15. 8.6.5 Canada
  16. 8.6.6 Mexico
9 Europe
  1. 9.1 Europe Oral Solid Dosage Pharmaceutical Formulation Revenue (2021-2032)
  2. 9.2 Europe Oral Solid Dosage Pharmaceutical Formulation Revenue by Type (2021-2032)
  3. 9.2.1 Europe Oral Solid Dosage Pharmaceutical Formulation Revenue by Type (2021-2026)
  4. 9.2.2 Europe Oral Solid Dosage Pharmaceutical Formulation Revenue by Type (2027-2032)
  5. 9.3 Europe Oral Solid Dosage Pharmaceutical Formulation Revenue Share by Type (2021-2032)
  6. 9.4 Europe Oral Solid Dosage Pharmaceutical Formulation Revenue by Application (2021-2032)
  7. 9.4.1 Europe Oral Solid Dosage Pharmaceutical Formulation Revenue by Application (2021-2026)
  8. 9.4.2 Europe Oral Solid Dosage Pharmaceutical Formulation Revenue by Application (2027-2032)
  9. 9.5 Europe Oral Solid Dosage Pharmaceutical Formulation Revenue Share by Application (2021-2032)
  10. 9.6 Europe Oral Solid Dosage Pharmaceutical Formulation Revenue by Country
  11. 9.6.1 Europe Oral Solid Dosage Pharmaceutical Formulation Revenue by Country (2021 VS 2025 VS 2032)
  12. 9.6.2 Europe Oral Solid Dosage Pharmaceutical Formulation Revenue by Country (2021-2026)
  13. 9.6.3 Europe Oral Solid Dosage Pharmaceutical Formulation Revenue by Country (2027-2032)
  14. 9.6.4 Germany
  15. 9.6.5 France
  16. 9.6.6 U.K.
  17. 9.6.7 Italy
  18. 9.6.8 Russia
  19. 9.6.9 Spain
  20. 9.6.10 Netherlands
  21. 9.6.11 Switzerland
  22. 9.6.12 Sweden
  23. 9.6.13 Poland
10 China
  1. 10.1 China Oral Solid Dosage Pharmaceutical Formulation Revenue (2021-2032)
  2. 10.2 China Oral Solid Dosage Pharmaceutical Formulation Revenue by Type (2021-2032)
  3. 10.2.1 China Oral Solid Dosage Pharmaceutical Formulation Revenue by Type (2021-2026)
  4. 10.2.2 China Oral Solid Dosage Pharmaceutical Formulation Revenue by Type (2027-2032)
  5. 10.3 China Oral Solid Dosage Pharmaceutical Formulation Revenue Share by Type (2021-2032)
  6. 10.4 China Oral Solid Dosage Pharmaceutical Formulation Revenue by Application (2021-2032)
  7. 10.4.1 China Oral Solid Dosage Pharmaceutical Formulation Revenue by Application (2021-2026)
  8. 10.4.2 China Oral Solid Dosage Pharmaceutical Formulation Revenue by Application (2027-2032)
  9. 10.5 China Oral Solid Dosage Pharmaceutical Formulation Revenue Share by Application (2021-2032)
11 Asia (Excluding China)
  1. 11.1 Asia Oral Solid Dosage Pharmaceutical Formulation Revenue (2021-2032)
  2. 11.2 Asia Oral Solid Dosage Pharmaceutical Formulation Revenue by Type (2021-2032)
  3. 11.2.1 Asia Oral Solid Dosage Pharmaceutical Formulation Revenue by Type (2021-2026)
  4. 11.2.2 Asia Oral Solid Dosage Pharmaceutical Formulation Revenue by Type (2027-2032)
  5. 11.3 Asia Oral Solid Dosage Pharmaceutical Formulation Revenue Share by Type (2021-2032)
  6. 11.4 Asia Oral Solid Dosage Pharmaceutical Formulation Revenue by Application (2021-2032)
  7. 11.4.1 Asia Oral Solid Dosage Pharmaceutical Formulation Revenue by Application (2021-2026)
  8. 11.4.2 Asia Oral Solid Dosage Pharmaceutical Formulation Revenue by Application (2027-2032)
  9. 11.5 Asia Oral Solid Dosage Pharmaceutical Formulation Revenue Share by Application (2021-2032)
  10. 11.6 Asia Oral Solid Dosage Pharmaceutical Formulation Revenue by Country
  11. 11.6.1 Asia Oral Solid Dosage Pharmaceutical Formulation Revenue by Country (2021 VS 2025 VS 2032)
  12. 11.6.2 Asia Oral Solid Dosage Pharmaceutical Formulation Revenue by Country (2021-2026)
  13. 11.6.3 Asia Oral Solid Dosage Pharmaceutical Formulation Revenue by Country (2027-2032)
  14. 11.6.4 Japan
  15. 11.6.5 South Korea
  16. 11.6.6 India
  17. 11.6.7 Australia
  18. 11.6.8 Taiwan
  19. 11.6.9 Southeast Asia
12 South America, Middle East and Africa
  1. 12.1 SAMEA Oral Solid Dosage Pharmaceutical Formulation Revenue (2021-2032)
  2. 12.2 SAMEA Oral Solid Dosage Pharmaceutical Formulation Revenue by Type (2021-2032)
  3. 12.2.1 SAMEA Oral Solid Dosage Pharmaceutical Formulation Revenue by Type (2021-2026)
  4. 12.2.2 SAMEA Oral Solid Dosage Pharmaceutical Formulation Revenue by Type (2027-2032)
  5. 12.3 SAMEA Oral Solid Dosage Pharmaceutical Formulation Revenue Share by Type (2021-2032)
  6. 12.4 SAMEA Oral Solid Dosage Pharmaceutical Formulation Revenue by Application (2021-2032)
  7. 12.4.1 SAMEA Oral Solid Dosage Pharmaceutical Formulation Revenue by Application (2021-2026)
  8. 12.4.2 SAMEA Oral Solid Dosage Pharmaceutical Formulation Revenue by Application (2027-2032)
  9. 12.5 SAMEA Oral Solid Dosage Pharmaceutical Formulation Revenue Share by Application (2021-2032)
  10. 12.6 SAMEA Oral Solid Dosage Pharmaceutical Formulation Revenue by Country
  11. 12.6.1 SAMEA Oral Solid Dosage Pharmaceutical Formulation Revenue by Country (2021 VS 2025 VS 2032)
  12. 12.6.2 SAMEA Oral Solid Dosage Pharmaceutical Formulation Revenue by Country (2021-2026)
  13. 12.6.3 SAMEA Oral Solid Dosage Pharmaceutical Formulation Revenue by Country (2027-2032)
  14. 12.6.4 Brazil
  15. 12.6.5 Argentina
  16. 12.6.6 Chile
  17. 12.6.7 Colombia
  18. 12.6.8 Peru
  19. 12.6.9 Saudi Arabia
  20. 12.6.10 Israel
  21. 12.6.11 UAE
  22. 12.6.12 Turkey
  23. 12.6.13 Iran
  24. 12.6.14 Egypt
13 Concluding Insights
    14 Appendix
    1. 14.1 Reasons for Doing This Study
    2. 14.2 Research Methodology
    3. 14.3 Research Process
    4. 14.4 Authors List of This Report
    5. 14.5 Data Source
    6. 14.5.1 Secondary Sources
    7. 14.5.2 Primary Sources

    GET THE RESEARCH

    Choose your license.

    Choose who needs access.
    All options are for this report and research series.

    Compare access permissions.

    Single User License
    One named user. Individual access.
    Multi User License
    Up to 5 users in the same department.
    Enterprise License
    Organization-wide access within the agreed license.

    Access applies to the purchased edition. Later editions are separate purchases.

    License options
    $4,950USD
    Buy now

    PDF by email within 3–5 working days after payment confirmation.

    Talk to an analyst
    APO Research
    Talk to an analyst